Peter de Haan
Gründer bei Amarna Therapeutics BV
Profil
Peter de Haan is the founder and Chief Scientific Officer of Amarna Therapeutics BV, which is founded in 2008.
He is currently a Non-Executive Director at Barranco Resources NL.
Aktive Positionen von Peter de Haan
| Unternehmen | Position | Beginn |
|---|---|---|
Barranco Resources NL
 Barranco Resources NL Wholesale DistributorsDistribution Services Barranco Resources NL provides mineral exploration services. The firm is also engaged in discovery, evaluation, and development of mineral resources. The company is headquartered in City Beach, Australia. | Direktor/Vorstandsmitglied | - |
Amarna Therapeutics BV
 Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | Gründer | 01.01.2008 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Barranco Resources NL
Barranco Resources NL Wholesale DistributorsDistribution Services Barranco Resources NL provides mineral exploration services. The firm is also engaged in discovery, evaluation, and development of mineral resources. The company is headquartered in City Beach, Australia. | Distribution Services |
Amarna Therapeutics BV
Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | Health Services |
